Skip to content
Review Open access

Oral anticoagulation with or without antiplatelet therapy for secondary stroke prevention in patients with atrial fibrillation and atherosclerosis: a systematic review and meta-analysis.

Nov 2026 · Journal of Thrombosis and Thrombolysis · 0 citations · 38 references
Medicine

Abstract

Patients with ischemic stroke (IS), atrial fibrillation (AF), and atherosclerosis have an increased risk of recurrent ischemic events. Addition of antiplatelet therapy (APT) to oral anticoagulant therapy (OAC) may offer additional protection against these events, at the cost of an increased risk of bleeding. This systematic review and meta-analysis aimed to compare the efficacy and safety of combined antithrombotic therapy versus OAC alone in this population. PubMed, Embase, and the Cochrane Central Register of Controlled Trials were searched from inception through September 2026 for randomized controlled trials and observational studies comparing OAC plus APT versus OAC alone in adults with IS, AF, and atherosclerosis. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using random-effects models. Risk of bias was assessed with RoB 2 and ROBINS-I. The protocol was registered in PROSPERO (CRD420251164174). Seven studies (4 retrospective, 2 prospective, 1 randomized trial; n= 9,924) were included. Combined therapy was not associated with a reduction in vascular composite outcome (HR 1.10, 95% CI 0.61-1.96), recurrent IS (HR 1.03, 95% CI 0.91-1.16), major bleeding (HR 1.17, 95% CI 0.86-1.59), or all-cause mortality (HR 0.90, 95% CI 0.60-1.36). In the subgroup with intracranial or extracranial atherosclerosis, combined therapy showed no significant difference in vascular composite risk (HR 1.67, 95% CI 0.83-3.33). Combined antithrombotic therapy with OAC plus APT was not associated with a reduction in recurrent IS, vascular composite outcome, major bleeding, or all-cause mortality in patients with IS, AF, and atherosclerosis. In patients with intracranial or extracranial atherosclerosis, combined therapy was not associated with a significant difference in the risk of the vascular composite outcome. These findings suggest that the addition of APT to OAC should be approached with caution in this population, and may be best reserved for select clinical contexts.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.